The 340B Drug Pricing Program, created by Congress to extend federal resources and improve patient care, is under scrutiny as new data shows charity care continues to decline year after year. ADAP Advocacy, as part of its 340B Project, has released a new infographic that reinforces the central message of its earlier policy paper and commercial, both titled "340B PROGRAM: The Glue That Should Hold Our Healthcare System Together." The infographic connects the dots on the program's unfettered growth and how that growth is failing to deliver on the program's promise.
What's particularly striking is that 340B drug purchases rose above $100 billion in 2025 across over 42,000 covered entities and over 32,000 pharmacies, yet charity care—free care and financial aid for poor patients, mandated by the Affordable Care Act—is on the decline. This disconnect suggests that the program's expansion has not translated into better care for vulnerable populations. Instead, the infographic highlights hospitals' declining charity, rising healthcare executive compensation, and exploding patient medical debt, among other issues.
The infographic continues ADAP Advocacy's '340B Too Big To Fail' national advocacy campaign, which argues that the program has grown too large to fail but is not meeting its intended goals. The campaign seeks to raise awareness about the need for reforms to ensure that the program's benefits reach the patients it was designed to help.
For those interested in learning more, the infographic can be downloaded online here: https://tinyurl.com/y6asjaw2. The release of this infographic matters because it adds to the growing body of evidence that the 340B program, despite its massive scale, is not achieving its core objective of improving patient care. As policymakers and stakeholders debate the future of the program, this visual tool provides a clear and compelling case for reform.
ADAP Advocacy's mission is to promote and enhance the AIDS Drug Assistance Programs (ADAPs) and improve access to care for persons living with HIV/AIDS. The organization works with advocates, community, health care, government, patients, pharmaceutical companies, and other stakeholders to raise awareness, offer patient educational programs, and foster greater community collaboration. By spotlighting the shortcomings of the 340B program, ADAP Advocacy aims to ensure that federal resources are used effectively to support the patients who need them most.
In conclusion, the new infographic from ADAP Advocacy serves as a critical reminder that the 340B Drug Pricing Program's growth has not been matched by a corresponding increase in charity care. This raises important questions about the program's accountability and effectiveness, and it underscores the need for continued advocacy and oversight to ensure that the program fulfills its original intent.
